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Rebecca S Kearney, on behalf of the UKSTAR trial collaborators*
Summary
Background Patients with Achilles tendon rupture who have non-operative treatment have traditionally been treated 
with immobilisation of the tendon in plaster casts for several weeks. Functional bracing is an alternative non-operative 
treatment that allows earlier mobilisation, but evidence on its effectiveness and safety is scarce. The aim of the 
UKSTAR trial was to compare functional and quality-of-life outcomes and resource use in patients treated non-
operatively with plaster cast versus functional brace.
Methods UKSTAR was a pragmatic, superiority, multicentre, randomised controlled trial done at 39 hospitals in 
the UK. Patients (aged ≥16 years) who were being treated non-operatively for a primary Achilles tendon rupture at the 
participating centres were potentially eligible. The exclusion criteria were presenting more than 14 days after injury, 
previous rupture of the same Achilles tendon, or being unable to complete the questionnaires. Eligible participants 
were randomly assigned (1:1) to receive a plaster cast or functional brace using a centralised web-based system. 
Because the interventions were clearly visible, neither patients nor clinicians could be masked. Participants wore the 
intervention for 8 weeks. The primary outcome was patient-reported Achilles tendon rupture score (ATRS) at 
9 months, analysed in the modified intention-to-treat population (all patients in the groups to which they were 
allocated, excluding participants who withdrew or died before providing any outcome data). The main safety outcome 
was the incidence of tendon re-rupture. Resource use was recorded from a health and personal social care perspective. 
The trial is registered with ISRCTN, ISRCTN62639639.
Findings Between Aug 15, 2016, and May 31, 2018, 1451 patients were screened, of whom 540 participants (mean age 
48·7 years, 79% male) were randomly allocated to receive plaster cast (n=266) or functional brace (n=274). 527 (98%) 
of 540 were included in the modified intention-to-treat population, and 13 (2%) were excluded because they withdrew 
or died before providing any outcome data. There was no difference in ATRS at 9 months post injury (cast group 
n=244, mean ATRS 74∙4 [SD 19∙8]; functional brace group n=259, ATRS 72∙8 [20∙4]; adjusted mean difference 
–1∙38 [95% CI –4∙9 to 2∙1], p=0·44). There was no difference in the rate of re-rupture of the tendon (17 [6%] of 
266 in the plaster cast group vs 13 [5%] of 274 in the functional brace group, p=0·40). The mean total health and 
personal social care cost was £1181 for the plaster cast group and £1078 for the functional bract group (mean 
between-group difference –£103 [95% CI –289 to 84]).
Interpretation Traditional plaster casting was not found to be superior to early weight-bearing in a functional brace, as 
measured by ATRS, in the management of patients treated non-surgically for Achilles tendon rupture. Clinicians may 
consider the use of early weight-bearing in a functional brace as a safe and cost-effective alternative to plaster casting.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Rupture of the Achilles tendon is an increasingly common 
injury in both the sporting and non-sporting populations, 
leading to a prolonged period away from work and social 
activities.1 The most recent trials comparing surgical repair 
with non-operative treatment have found no dif erence in 
functional outcome; therefore, non-operative treatment is 
increasingly preferred by clinicians and patients.2–4
Traditionally, patients with an Achilles rupture have 
been treated with serial plaster casts over several weeks. 
The cast provides maximum protection for the tendon 
as it heals, but immobilisation might increase calf 
muscle atrophy, ankle joint stifness, gait abnormalities, 
and the risk of blood clots.5–7 Functional bracing is an 
alternative treatment in which the patient’s lower leg is 
placed into a removable walking boot which contains 
wedges to lift up the heel. The brace allows the patient 
to put weight through their leg as they walk and can be 
removed to allow movement at the ankle joint. However, 
evidence is scarce on how functional bracing afects 
overall recovery and whether it is associated with an 
increased risk of re-rupture of the tendon.8
Lancet 2020; 395: 441–48
See Comment page 397
*UKSTAR trial collaborators are 
listed at the end of the Article
Oxford Trauma 
(Prof M L Costa PhD, 
J Achten PhD, Prof S E Lamb PhD) 
and Oxford Clinical Trials 
Research Unit, Centre for 
Statistics in Medicine 
(I R Marian MSc, S J Dutton MSc), 
Nuffield Department of 
Rheumatology, 
Musculoskeletal and 
Orthopaedic Sciences, 
University of Oxford, Oxford, 
UK; College of Medicine and 
Health, University of Exeter, 
Exeter, UK (Prof S E Lamb); 
Division of Rheumatology, 
Orthopaedics and 
Dermatology, School of 
Medicine, University of 
Nottingham, Nottingham, UK 
(B Ollivere MD); Warwick 
Clinical Trials Unit, University 
of Warwick, Coventry, UK 
(M Maredza PhD, 
Prof S Petrou PhD, 
R S Kearney PhD); and Nuffield 
Department of Primary Care 
Health Sciences, University of 
Oxford, Oxford, UK 
(Prof S Petrou)
Correspondence to: 
Prof Matthew Costa, Oxford 
Trauma, Nuffield Department of 
Rheumatology, Musculoskeletal 
and Orthopaedic Sciences, 
University of Oxford, 
Oxford OX3 9DU, UK 
matthew.costa@ndorms.ox.
ac.uk
Articles
442 www.thelancet.com   Vol 395   February 8, 2020
The objective of the UKSTAR trial was to compare 
function and pain, quality of life, complications (including 
re-rupture), and resource use in patients having non-
operative treatment for an acute Achilles tendon rupture, 
treated with plaster cast versus functional bracing.
Methods
Study design
UKSTAR was a pragmatic, superiority, multicentre, 
randomised controlled trial done at 39 National Health 
Service (NHS) hospitals in the UK. The study was given a 
favourable Research Ethics opinion by the Oxford B 
Research Ethics Committee on April 7, 2016 (reference 
16/SC/0109) and each recruitment centre was granted 
site-specific approval from its NHS Trust Research and 
Development department before trial commence ment. 
The detailed protocol and statistical analysis plan have 
been published previously.9,10
Participants
All patients aged 16 years or older who presented at the 
trial centres with a primary (first-time) rupture of the 
Achilles tendon were screened. The patient, in con junction 
with their surgeon, decided whether non-surgical treat-
ment was appropriate, as per normal clinical practice. If 
patients decided not to have surgery, they were potentially 
eligible to take part in the trial. Patients were excluded 
if they presented more than 14 days after their injury, 
had experienced a previous rupture of the same Achilles 
tendon, or were unable to complete questionnaires. 
Eligible patients were provided with the trial information 
verbally and in writing. When the patient had considered 
the trial information, informed written consent was 
obtained by a trained member of the research team.
Randomisation and masking
Participants were randomly allocated (1:1) to either func-
tional bracing or plaster cast using a computer-generated 
allocation sequence stratified by recruitment centre via a 
secure, centralised web-based randomisation service. 
The sequence was prepared by the trial statistician. 
Stratifi cation by recruitment centre helped to ensure any 
cluster efect related to the recruitment centre itself was 
equally distributed in the trial groups. A local research 
associate informed the treating clinical team of the 
allocated treatment. Because the interventions were 
clearly visible, neither patients nor clinicians could be 
masked.
Procedures
The interventions were chosen on the basis of a sys-
tematic review of the literature and a survey of current 
UK clinical practice; plaster casting is the most common 
treatment, and rigid braces are used more commonly 
Research in context
Evidence before this study
In the past 10 years, trials comparing surgical repair with 
non -surgical treatment for patients with a rupture of the 
Achilles tendon have found no evidence of a difference in 
funct ional outcome; therefore, non-surgical treatment is 
increasingly preferred. However, before this study, little 
evidence was available on the best type of non-surgical 
treatment. Traditionally, patients have been treated in plaster 
casts to immobilise the foot and ankle while the tendon heals. 
However, this approach has an immediate effect on mobility 
for a period of around eight weeks, affecting activities of daily 
life. Prolonged immobilisation is associated with risk of muscle 
atrophy, deep vein thrombosis, and joint stiffness. In addition, 
it has potential long-term consequences, including prolonged 
gait abnormalities, persistent calf muscle weakness, and an 
inability to return to previous activity levels. Functional 
bracing, involving immediate, protected weight-bearing in a 
brace, was designed to address these issues. However, before 
the UKSTAR trial, little evidence regarding its effectiveness was 
available, and some clinicians had concerns about safety, 
in particular the risk of re-rupture of the tendon. In guidelines 
published in 2009, the American Academy of Orthopaedic 
Surgeons (AAOS) stated that it was unable to recommend for 
or against the use of functional bracing for patients with 
Achilles tendon rupture treated non-operatively. We updated 
this evidence synthesis in 2019 by doing a literature search of 
MEDLINE and Embase with the terms “Achilles tendon” AND 
“rupture” for articles published in English from 2009 (date of 
the AAOS guidelines) to October, 2019. To our knowledge, 
the only trials published to date have been single-centre 
studies with small patient numbers and inconclusive findings.
Added value of this study
In the UKSTAR trial, 540 adult participants at 39 hospitals in the 
UK were randomly assigned to either plaster cast or functional 
brace for non-surgical treatment of an Achilles tendon rupture. 
The study found no evidence that traditional plaster casting is 
superior to early weight-bearing in a functional brace as 
measured by Achilles tendon rupture score. The results also 
showed no evidence of a difference in the rate of re-rupture of 
the tendon. A health economic analysis indicated that 
functional bracing is likely to be cost-effective.
Implications of all the available evidence
Rupture of the Achilles tendon is a serious and increasingly 
common injury. In keeping with the latest evidence, patients 
are increasingly choosing to have their tendon treated 
non-surgically. However, to date, little evidence was available 
on the best type of non-surgical treatment. The findings of the 
UKSTAR trial will assist patients and clinicians in choosing the 
most suitable non-surgical treatment. Furthermore, policy 
makers will note that the health economic evaluation indicates 
that functional bracing is likely to be cost-effective.
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than flexible orthotics.4,8 Images of the two treatments 
are provided in the appendix (p 2).
Participants who were randomly allocated to the plaster 
cast group had a below-knee plaster cast applied in the 
gravity equinus position (ie, the position that the foot 
naturally adopts when unsupported, with the toes 
pointing down towards the floor). Over the first 8 weeks, 
the participants returned to the hospital (the frequency of 
visits was decided by the clinical team at that hospital)
and the position of the plaster cast was gradually changed 
until the foot was in a plantigrade position (ie, the foot 
was flat to the floor). At this point, usually 6 weeks after 
the first cast was applied, the patient was permitted to 
start fully weight-bearing in the plaster cast. The cast was 
removed at 8 weeks.
Participants who were randomly allocated to the 
functional brace group had a removable, rigid walking 
boot. Initially, two solid heel wedges (or equivalent) 
were inserted inside the brace to replicate the gravity 
equinus position of the foot.11 However, because the 
bottom of the brace was flat to the floor, the participant 
was able to mobilise with their full weight on their foot 
immediately after fitting. The brace also permitted some 
movement at the ankle joint. The number of wedges 
and foot position were reduced over 8 weeks until 
the foot reached a plantigrade position. The brace was 
removed at 8 weeks.
At 8 weeks, all participants were provided with the 
same standardised, written physiotherapy advice detailing 
the exercises they needed to perform for rehabilitation 
(appendix p 1). This standardised rehabilitation advice was 
based on a pub lished systematic review of rehabilitation 
protocols and refined through a previous feasibility trial.8 
All par ticipants were advised to move their toes, ankle 
joint, and knee joint fully within the limits of their 
comfort, and walking was encouraged. In this pragmatic 
trial, any other rehabilitation input beyond the written 
physiotherapy advice (including a formal referral to 
physiotherapy) was recorded but left to the discretion of 
the treating clinicians, as per their normal clinical practice. 
Patients were assessed for outcomes at 8 weeks and 
followed up at 3, 6, and 9 months from randomisation. 
All primary and secondary outcomes were assessed at all 
visits.
Outcomes
The primary outcome was Achilles tendon rupture 
score (ATRS) at 9 months.12 ATRS is patient-reported and 
consists of 10 items that assess symptoms, physical activity, 
and pain related to the Achilles tendon to give a score 
between 0 and 100, with 100 as the best possible score.
The secondary outcomes were ATRS at other timepoints, 
health-related quality of life (measured by EQ-5D-5L),13 and 
complications (tendon re-rupture, deep vein thrombosis, 
pulmonary embolism, fall with no injury, fall with injury, 
pain under the heel, numbness around the foot, and 
pressure sores).
Statistical and health economic analysis
The minimum clinically important diference (MCID) 
for the primary outcome ATRS was 8 points. At an 
individual patient level, a diference of 8 points repre-
sents the ability to walk upstairs or run with some 
difficulty versus with great difficulty. At the population 
level, 8 points represents the diference between a 
healthy patient and a patient with a minor disability.14 In 
our pilot work, the standard deviation of the ATRS at 
9 months post injury was 20 points.15 Assuming a likely 
population variability of 20, MCID value of 8, 90% power 
to detect the selected MCID, and a 5% type 1 error rate 
on a two-sided test, we required 264 total participants 
to be randomised. Allowing a margin of 20% loss of 
primary outcome data to include patients who would 
cross over between interventions or be lost to follow-up, 
we required a minimum of 330 participants. Recruitment 
was faster than anticipated, and, with the approval of the 
Research Ethics Committee, we were able to exceed the 
minimum number of participants required in the sample 
size calculation to obtain a more precise estimate of the 
number of complications.
The primary outcome of ATRS at 9 months was ana-
lysed in a modified intention-to-treat population. We also 
considered the complier average causal efect (CACE) 
population to account for compliance with treatment.16 
The modified intention-to-treat population included all 
participants in their randomised groups, excluding 
participants who had missing data at baseline, or who 
withdrew or died before providing any outcome data. The 
CACE population included all randomised participants 
who were compliant with treatment. Participants were 
considered compliant with the intervention if they wore 
their allocated treatment for a period of 6 weeks or more 
without any change of treatment within this period. We 
used a linear mixed efects regression model, adjusting 
for age, gender, and baseline ATRS as fixed efects, 
and recruitment centre and repeated measures within 
participants as random efects. Secondary outcomes 
were analysed in the modified intention-to-treat popu-
lation, with use of similar methods adjusting for the 
relevant baseline covariate if applicable. Complications 
were analysed using χ² or Fisher’s exact test in the inten-
tion-to-treat population. Sensitivity analyses to examine 
the robustness of conclusions to diferent assumptions 
were done in the CACE population. All analyses were 
done using Stata version 15.0 (StataCorp, College Station, 
TX, USA).
The health economic evaluation adopted an NHS and 
personal social services perspective, in accordance with 
UK National Institute for Health and Care Excellence 
recommendations.17 A societal perspective for costs was 
adopted for the sensitivity analysis and this included 
private costs incurred by trial participants and their 
families, and productivity losses and loss of earnings as 
a result of work absences. The economic evaluation was 
a cost-utility analysis, expressed in terms of incremental 
See Online for appendix
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cost per quality-adjusted life-year (QALY) gained. The 
time horizon covered the period from randomisation to 
end of follow-up at 9 months post injury. Economic 
costs associated with the direct delivery of the inter-
ventions were estimated and included costs of the 
walking boot and wedges, materials used for plaster 
casts, and the costs associated with fitting the inter-
ventions to patients (hospital staf time). Resource-use 
questionnaires com pleted by participants at each 
follow-up timepoint provided a profile of broader NHS 
and personal social services resource use. Resource-use 
values were con verted into costs (in GBP, 2017–18 
prices) by applying unit costs obtained from key UK 
national databases.18–20 Further details of costing pro-
cedures are provided in the appendix (pp 3–5). QALY 
profiles were calculated for each participant using 
health utility scores generated from the EQ-5D-5L and 
assuming linear interpolation between baseline and 
follow-up health utility scores. Bivariate regression of 
costs and QALYs, with multiple imputation for missing 
data, was conducted in order to estimate the incremental 
cost per QALY gained for functional bracing compared 
with plaster cast. Further more, the probability of cost-
efectiveness of functional bracing was estimated over a 
range of cost-efectiveness thresholds: £15 000, £20 000, 
and £30 000 per QALY gained.17,21 Further details on the 
methods of the economic evaluation and the sensitivity 
analyses done to test the robustness of cost-efectiveness 
results are provided in the appendix (pp 5, 6).
The trial is registered with ISRCTN, ISRCTN62639639.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Aug 15, 2016, and May 31, 2018, 1451 patients 
were screened, of whom 540 partici pants were randomly 
allocated to receive plaster cast (n=266) or functional brace 
(n=274; figure). One participant in each group withdrew 
consent immediately pre-treatment. Participants had a 
mean age of 48∙7 years (SD 13·8), were predominantly 
male (426 [79%] of 538), and most commonly ruptured 
their tendon during sports (70%). The study groups were 
well balanced on all baseline characteristics (table 1). 
13 partici pants were excluded from the modified inten-
tion-to-treat population, because they had missing data 
at baseline (n=4), or withdrew (n=8) or died (n=1) before 
providing any outcome data. 527 (98%) participants were 
included in the primary outcome analysis.
There was no statistically or clinically significant dif er-
ence in ATRS at 9 months post injury in the plaster cast 
group (mean ATRS 74∙4 [SD 19∙8]) versus the func tional 
brace group (72∙8 [20∙4]; adjusted mean diference 
–1∙38 [95% CI –4∙9 to 2∙1]; table 2). There was no 
statistically significant diference in the secondary CACE 
analysis (adjusted mean diference –1∙18 (–4∙5 to 2∙1). 
We found a statistically significant but clinically equivocal 
diference in ATRS at 8 weeks post injury in favour 
of functional brace (adjusted mean diference 5∙53 
[2∙0–9∙1]), but not at 3 months or 6 months post injury. 
Health-related quality of life, measured by EQ-5D-5L, 
Figure: Trial profile
ATRS=Achilles tendon rupture score. ITT=intention-to-treat. *Two participants were randomised in error without 
giving consent to be in the study, and they immediately withdrew as shown; these participants were excluded 
from all data analyses. †Includes one patient who withdrew pre-treatment and five patients who withdrew post-
treatment. ‡Includes one patient who withdrew pre-treatment and one patient with withdrew post-treatment.
266 allocated to plaster cast 
1 withdrew
540 patients randomised*
1451 patients referred to the trauma or orthopaedic 
clinic with Achilles tendon rupture
1076 eligible patients
1 withdrew
274 allocated to functional brace 
257 included in modified ITT analysis 270 included in modified ITT analysis
265 received treatment
247 received plaster cast
17 received functional brace
13 patient decision
3 clinician decision 
1 incorrect diagnosis
1 unknown
273 received treatment
269 received functional brace
4 received plaster cast
1 patient decision
1 clinician decision
2 medical resources 
unavailable
375 patients did not meet eligibility criteria
3 younger than 16 years
37 previous Achilles tendon rupture
120 receiving surgery
155 presented to treating hospital >14 days after 
injury
46 unable to adhere to trial procedures or complete 
questionnaire
14 other reasons
534 not randomised 
97 no staff available to register patient or patient 
missed in error
50 choice of clinician
2 walking boot functional brace or plaster cast 
supplies unavailable
385 patient declined
9 excluded from modified 
ITT analysis
6 withdrew†
3 missing data
4 excluded from modified 
ITT analysis
2 withdrew‡
1 missing data
1 death
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showed the same pattern, with a statistically significant 
diference at 8 weeks post injury but not at later 
timepoints (appendix p 15). There was no evidence of a 
diference in the complication profiles between groups 
(table 3). 17 (6%) of 266 participants in the plaster cast 
group had re-rupture of the tendon, compared with 
13 (5%) in the functional brace group.
The mean direct intervention costs were £36 for the 
plaster cast group compared with £109 for the functional 
brace group (mean diference £73 [95% CI 67–79]; 
p<0·0001). The mean total NHS and personal social 
services cost throughout the entire follow-up period for 
the base case (imputed) analysis was £1181 for the plaster 
cast group and £1078 for the functional brace group. 
Although functional bracing was slightly cheaper, the 
mean between-group cost diference of –£103 (95% CI 
–289 to 84) was not statistically significant. The QALY 
estimate for the base case was slightly higher for patients 
in the functional brace group (0∙015 QALYs [95% CI 
–0∙001 to 0∙030]) over the 9-month follow-up period. 
The incremental cost-efectiveness ratio for the base-case 
Plaster cast 
(n=264)
Functional 
brace (n=274)
Overall 
(n=538)
Gender
Female 51 (19%) 61 (22%) 112 (21%)
Male 213 (81%) 213 (78%) 426 (79%)
Age, years 49·0 (14·0) 48·3 (13·8) 48·7 (13·8)
ATRS pre-injury
n 264 273 537
Median (IQR) 100·0 
(96·5–100·0)
100·0 
(94·0–100·0)
100·0 
(96·0–100·0)
BMI, kg/m²
n 255 265 520
Mean (SD) 27·5 (4·5) 27·8 (5·0) 27·7 (4·8)
Days since injury 5·0 
(2·5–8·0)
5·0 
(2·0–8·0)
5·0 
(2·0–8·0)
Mechanism of injury
Fall from height 3 (1%) 8 (3%) 11 (2%)
Fall on steps or stairs 22 (8%) 14 (5%) 36 (7%)
Fall or trip from 
standing height
6 (2%) 11 (4%) 17 (3%)
Pushing an object 18 (7%) 15 (5%) 33 (6%)
Sports 187 (71%) 192 (70%) 379 (70%)
Walking 14 (5%) 28 (10%) 42 (8%)
Other 14 (5%) 6 (2%) 20 (4%)
Side of injury
Right 122 (46%) 138 (50%) 260 (48%)
Left 142 (54%) 136 (50%) 278 (52%)
Regular smoker
No 225 (85%) 234 (85%) 459 (85%)
Yes 39 (15%) 39 (14%) 78 (14%)
Missing 0 1 (<1%) 1 (<1%)
Cigarettes per day
n 39 39 78
Median (IQR) 10 
(5–15)
10 
(5–15)
10 
(5–15)
Smoking duration, years
n 38 38 76
Median (IQR) 20·0 
(10·0–25·0)
20·5 
(13·0–30·0)
20·0 
(10·0–30·0)
Alcohol units per week
0–7 162 (61%) 161 (59%) 323 (60%)
8–14 49 (19%) 65 (24%) 114 (21%)
15–21 40 (15%) 35 (13%) 75 (14%)
>21 12 (5%) 10 (4%) 22 (4%)
Missing 1 (<1%) 3 (1%) 4 (1%)
(Table 1 continues in next column)
Plaster cast 
(n=264)
Functional 
brace (n=274)
Overall 
(n=538)
(Continued from previous column)
Taking medication
Fluoroquinolone 
antibiotics
5 (2%) 4 (2%) 9 (2%)
Steroids 7 (3%) 14 (5%) 21 (4%)
DMARDs 2 (1%) 1 (<1%) 3 (1%)
Diabetic medication 5 (2%) 14 (5%) 19 (4%)
Regular analgesia 23 (9%) 14 (5%) 37 (7%)
Anticoagulant 
medication
66 (25%) 78 (29%) 144 (27%)
Diagnosis before injury
Diabetes 5 (2%) 18 (7%) 23 (4%)
Rheumatoid arthritis 0 3 (1%) 3 (1%)
Lower limb fracture 
(past 12 months)
1 (<1%) 4 (1%) 5 (1%)
Ligament, tendon, or 
nerve injury to lower 
limb (past 12 months)
5 (2%) 8 (3%) 13 (2%)
Arthritis 21 (8%) 21 (8%) 42 (8%)
Achilles tendinopathy 10 (4%) 10 (4%) 20 (4%)
Employment status
Full-time employed 160 (61%) 168 (61%) 328 (61%)
Part-time employed 18 (7%) 15 (5%) 33 (6%)
Self-employed 39 (15%) 29 (11%) 68 (13%)
Retired, looking after 
home, or inactive
35 (13%) 41 (15%) 76 (14%)
Unpaid work 1 (<1%) 2 (1%) 3 (1%)
Unemployed 8 (3%) 8 (3%) 16 (3%)
Full-time student 3 (1%) 9 (3%) 12 (2%)
Missing  0 2 (1%) 2 (<1%)
Employment category
Unskilled manual 11 (4%) 11 (4%) 22 (4%)
Skilled manual 62 (23%) 64 (23%) 126 (23%)
Unskilled non-manual 6 (2%) 7 (3%) 13 (2%)
Skilled non-manual 29 (11%) 21 (8%) 50 (9%)
Professional 109 (41%) 108 (39%) 217 (40%)
Missing 0 3 (1%) 3 (1%)
Data are n (%) for categorical variables and mean (SD) or median (IQR) for 
continuous outcomes unless stated otherwise. ATRS=Achilles tendon rupture 
score. BMI=body-mass index. DMARD=disease-modifying antirheumatic drug.
Table 1: Baseline characteristics
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analysis showed that functional bracing was the dominant 
procedure because the functional brace group incurred 
slightly lower costs and experienced slightly higher 
QALYs over the follow-up period. The probability of cost-
efectiveness for func tional bracing was 0·97 at a cost-
efectiveness threshold of £20 000 per QALY gained. This 
finding remained robust to most sensitivity analyses; 
the exception was an assessment of cost-efectiveness 
from a societal perspective in which the probability of 
cost-efectiveness for functional bracing was 0∙58. Further 
results of the economic evaluation are provided in the 
appendix (pp 7–20).
Discussion
The findings of this study showed no diference in ATRS 
at 9 months between plaster cast and functional bracing 
for patients treated non-operatively for a rupture of 
the Achilles tendon. There was a statistically significant 
diference in ATRS at 8 weeks in favour of the functional 
brace group, although the clinical significance of this 
diference is debatable. Any benefit to functional bracing 
at 8 weeks was not evident later in recovery, with similar 
scores between groups at 3, 6, and 9 months. Health-
related quality of life showed a similar pattern of recovery 
over time. The diference in EQ-5D-5L utility score was 
significant early in the patients’ recovery, but there was 
no evidence of a diference at 9 months.
The safety profile of the functional brace was another 
important consideration of this trial. Specifically, if the 
risk of re-rupture of the tendon were higher in patients 
who were allowed to fully weight-bear in a functional 
brace, this would influence the decision to choose this 
treatment, even if patient-reported outcomes were 
similar. We found that the risk of re-rupture was 
generally lower than that reported in the literature,22 
with 17 (6%) patients experiencing re-rupture in the 
plaster cast group and 13 (5%) in the functional brace 
group. None of the re-ruptures occurred more than 
6 months after the injury.
When UKSTAR was developed, the scarcity of evidence 
in this area was recognised in the 2009 American 
Academy of Orthopaedic Surgeons guideline,23 which 
concluded that “For patients treated non-operatively, 
we are unable to recommend for or against the use of 
immediate func tional bracing for patients with acute 
Achilles tendon rupture.” Since the start of the UKSTAR 
trial, a number of small randomised trials have inves-
tigated both the mech an istic and functional efects of 
early weight-bearing in a brace versus cast immo bilisation 
for patients treated non-operatively. One trial investigated 
the bio mechanical properties of the hea ling tendon in 
patients randomly allocated to early weight-bearing 
versus delayed weight-bearing.24 The inves tigators noted 
that the group treated with early weight-bearing expe-
rienced less tendon stifness. However, in terms of 
functional outcomes, the authors reported no evidence of 
a diference.25 A second trial of 47 participants inves-
tigated weight-bearing in patients treated non-operatively 
for an acute Achilles tendon rupture. Half of the patients 
were treated with partial weight-bearing beginning on 
the first day of treatment and the other half with 
non-weight-bearing for the first 4 weeks. The authors 
concluded that early weight-bearing was safe, in terms of 
the incidence of re-rupture, but they found no evidence 
of a diference in functional outcome in the first 
12 months after the rupture.26 Another trial of 84 patients 
compared two types of cast immobilisation of the 
Achilles tendon rupture.27 Half of the patients wore a 
traditional cast, which restricted weight-bearing, and 
the other group wore a modified cast which included a 
heel iron to facilitate weight-bearing. The authors found 
no evidence of a diference in func tional outcome. One 
further study, published in 2019,28 randomly allocated 
130 patients to cast immo bilisation or early controlled 
motion at a single centre. The authors found no evidence 
that early controlled motion was of benefit compared 
with immobilisation in any of the investigated outcomes.
The strengths of the pragmatic UKSTAR trial were the 
use of multiple centres and clinicians reflecting the care 
provided across the UK NHS, the large number of 
participants with 93% complete follow-up, and the use of 
validated patient-reported outcomes.
As in all clinical trials, some patients declined to 
participate. In this trial, we approached only individuals 
Plaster cast Functional brace Between-group difference (95% CI) p value
n ATRS, mean 
(SD)
n ATRS, mean 
(SD)
Unadjusted Adjusted*
8 weeks 234 35·3 (20·1) 240 40·3 (17·8) 4·98 (1·3 to 8·7) 5·53 (2·0 to 9·1) 0·0024
3 months 229 44·4 (21·1) 244 45·6 (20·4) 1·23 (–2·5 to 4·9) 1·76 (–1·8 to 5·3) 0·34
6 months 224 63·9 (21·4) 235 63·5 (23·0) –0·44 (–4·2 to 3·3) 0·35 (–3·3 to 4·0) 0·85
9 months 244 74·4 (19·8) 259 72·8 (20·4) –1·65 (–5·2 to 1·9) –1·38 (–4·9 to 2·1) 0·44
The analysis was based on a mixed effects model with repeated measures from all timepoints. ATRS=Achilles tendon 
rupture score. *ATRS analysis adjusted for recruitment centre, age, gender, and baseline ATRS with repeated 
observations within participant.
Table 2: ATRS in the modified intention-to-treat population
Plaster cast 
(n=266)
Functional 
brace (n=274)
p value
Tendon re-rupture 17 (6%) 13 (5%) 0·40
Deep vein thrombosis 3 (1%) 6 (2%) 0·51
Pulmonary embolism 0 2 (1%) 0·50
Fall with no injury 60 (23%) 53 (19%) 0·36
Fall with injury sustained 21 (8%) 24 (9%) 0·72
Pain under the heel 158 (59%) 180 (66%) 0·13
Numbness around the foot 108 (41%) 130 (47%) 0·11
Pressure sores 39 (15%) 51 (19%) 0·22
Data are number of participants reporting complication at least once (%). 
Complications in each treatment group were summed over the 9-month follow-up.
Table 3: Complications from baseline to 9 months in the intention-to-
treat population
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who had already decided against surgical repair. The 
proportion of people accepting the invitation to par tici-
pate was high, with most of those declining doing so 
because of an unwillingness to participate in research. 
Therefore, we believe the results to be generalisable to 
the population of patients having non-operative treat-
ment for an acute rupture of the Achilles tendon. 
A further anticipated limitation was crossover from the 
allocated trial treatment. However, most participants 
received their allocated treatment with only 21 patients 
changing their allocated intervention after being 
randomised. In addition, some patients had incomplete 
compliance with treatment. The ability to bear weight 
immediately within a functional brace might have moti-
vated patients to change from plaster cast to functional 
brace, given that these were most of the crossovers, 
rather than the other way around. However, the overall 
number of patients not receiving their allocated 
treatment is small and the CACE analysis, which was 
adjusted for incomplete compliance, confirmed the 
result of the primary analysis showing no evidence of a 
diference in ATRS between the two groups. Loss to 
follow-up is another potential limitation. However, over 
93% of participants provided primary outcome data 
at 9 months, which is considerably higher than the 
80% assumed in the trial design. Therefore, given that 
the trial also exceeded the minimum sample size, we can 
be confident that the conclusions based on the primary 
outcome are robust and the risk of type II error is low.
In conclusion, this trial provides no evidence that 
traditional plaster casting is superior to early weight-
bearing in a functional brace as measured by ATRS in 
the management of patients treated non-operatively for 
Achilles tendon rupture. The use of functional bracing is 
likely to be cost-efective.
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